InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical drug development company focused on proprietary small-molecule candidates for diseases with high unmet medical need. Through its BayMedica subsidiary, it also manufactures and sells bulk rare, non-intoxicating cannabinoids as ingredients for health and wellness applications.
Fiscal year 2026 · change from previous year
Development 2021–2026
Business
Share of revenueEarly-stage proprietary compounds being developed for ocular, dermatology and neurodegenerative indications.
Bulk rare cannabinoids manufactured and sold to B2B customers for health and wellness uses.
Research, formulation, CMC and clinical development work supporting pipeline advancement.
Proprietary and conventional manufacturing approaches used to produce high-purity cannabinoid products.
Customers
InMed’s commercial customers are B2B buyers of rare cannabinoid raw materials, likely including ingredient formulators and health-and-wellness product companies. On the pharmaceutical side, the company’s end customers are future patients, but near-term economic value depends on regulators, clinical investigators, and potential licensing or partnership counterparties. The business is therefore split between ingredient sales today and long-duration drug development programs that may monetize through approval or partnering.
Buy bulk rare, non-intoxicating cannabinoids for use as raw materials in health and wellness products.
May license or co-develop INM-755 and other pipeline assets to reduce development risk and fund advancement.
CROs, CDMOs, investigators and consultants supporting preclinical and clinical development work.
Patients with dry AMD, epidermolysis bullosa, itch-related skin conditions and Alzheimer’s disease.
Strategy
InMed is prioritizing advancement of its proprietary pipeline while keeping BayMedica’s cannabinoid ingredient business as the current revenue base. Management is also pursuing strategic partnership opportunities for INM-755 and scaling CMC work for INM-901 to support future clinical entry and potential licensing value.
Clinical progress is the main path to value creation for a company with no approved products.
Commercial sales provide the only recurring revenue source while the pharma pipeline remains pre-revenue.
Partnering can reduce capital intensity and improve the odds of advancing assets like INM-755.
Geography
InMed is headquartered in Vancouver, British Columbia, and is listed on Nasdaq in the United States. Its business is cross-border: development, manufacturing and commercial activities are influenced by U.S. and Canadian regulation, while trade policy and import/export conditions can affect BayMedica’s ingredient business.
Risks
InMed is highly exposed to clinical, regulatory and financing risk because its drug candidates are early-stage and unapproved. The BayMedica business adds commercial and policy risk, including possible inventory write-offs, trade disruption and regulatory changes affecting cannabinoid ingredients.
- Clinical development failureImpact: HighLikelihood: High
Product candidates are early stage and may not demonstrate safety or efficacy in trials.
Exposure - Regulatory approval delay or denialImpact: HighLikelihood: High
Drug candidates require lengthy and unpredictable FDA/Health Canada review processes.
Exposure: All pipeline programs
- Cannabinoid market and policy changeImpact: HighLikelihood: High
BayMedica’s commercial inventory and sales depend on the legal treatment of non-intoxicating cannabinoids.
Exposure: BayMedica commercial business
- Financing and going-concern pressureImpact: HighLikelihood: High
The company has recurring operating losses and relies on external capital to fund operations.
Exposure: Corporate liquidity
- Nasdaq minimum bid price or listing complianceImpact: MediumLikelihood: Low
Delisting risk can reduce liquidity and access to capital for a small-cap development company.
Exposure: Common shares on Nasdaq Capital Market
Accounting
Judgemental itemsCommercial sales are recognized when control transfers, so shipment timing affects quarterly revenue.
Impact: BayMedica sales and gross margin
Management must evaluate whether cash resources are sufficient to continue operations.
Impact: Liquidity disclosure and investor perception
Rare cannabinoid inventory may need write-downs if regulation or demand weakens.
Impact: Cost of sales and asset values
Equity-linked awards and warrants require fair value estimates that affect operating expenses.
Impact: Reported net loss and equity
Clinical, CRO and patent-related costs require judgment in period-end accruals.
Impact: Research and development expense
Similar listed companies
Publicly listed companies with a comparable business focus.
INSMED Inc
INSM · Pharmaceutical Preparations
INSMED Inc is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for serious respiratory and other high-unmet-need diseases.
Marimed Inc.
MRMD · Medicinal Chemicals & Botanical Products
cbdMD, Inc.
YCBD · Perfumes, Cosmetics & Other Toilet Preparations
IM Cannabis Corp.
IMCC · Medicinal Chemicals & Botanical Products
Dogwood Therapeutics, Inc.
DWTX · Pharmaceutical Preparations
Psyence Biomedical Ltd
PBMWW · Pharmaceutical Preparations
Last updated: 24/09/2026